According to the research report titled ‘U.S. Non-Invasive Prenatal Testing Market - Growth, Demand, Trends, Opportunity, Forecasts (2020 - 2027)’ available with Market Study Report, U.S. non-invasive prenatal testing market is anticipated to reflect a valuation of USD 2.2 billion by the year 2027.
 

Escalating risk of chromosomal abnormalities, growing maternal age, and increasing prevalence of chromosomal aneuploidies in fetus are major factors augmenting the growth of U.S. non-invasive prenatal testing market size.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2915595/
 

Furthermore, emergence of innovative non-invasive prenatal testing (NIPT) products, growing cognizance of testing procedures, rising focus towards reimbursement of non-invasive techniques are further boosting the industry expansion.
 

Additionally, increasing consumer preference towards adopting NIPT over invasive methods coupled with favorable regulations for the adoption of the method for pregnancy treatments are further stimulating the U.S. non-invasive prenatal testing market outlook.
 

The report on ‘U.S. non-invasive prenatal testing market’ offers a comprehensive analysis with accentuation on the primary growth catalysts, opportunities, and restraints shaping the market dynamics.
 

In hindsight of the COVID-19 pandemic, the document addresses the fluctuations in the supply chain of the industry and assists stakeholders in taking well-informed decisions in order to adapt to the market uncertainties.
 

Lastly, the report highlights the competitive landscape and provides an in-depth analysis of the leading organizations operating in this business sphere.  The study also elaborates on the major development trends among market majors such as mergers & acquisitions as well as innovative product launches.
 

Speaking of which, major players that outline the U.S. non-invasive prenatal testing industry trends are Integrated Genetics, Ariosa Diagnostics, Inc., Agilent Technologies, Inc., Invitae Corporation, Yourgene Health PLC, PerkinElmer, Inc., Progenity, Inc., GenPath, Centogene AG, Myriad Genetics, Inc., Quest Diagnostics, Natera Inc., and Illumina, Inc.